April 15, 2024 05:28 AM EDTUpdated April 24, 03:40 PM

Astellas writes down another piece of its Audentes gene therapy acquisition

Astellas will take a $450 million (70 billion Japanese yen) hit in its latest quarter as it writes down the value of a preclinical gene …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Astel­las writes down an­oth­er piece of its Au­dentes gene ther­a­py ac­qui­si­tion